The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis.

Metalloproteases are important in many aspects of biology, ranging from cell proliferation, differentiation and remodeling of the extracellular matrix (ECM) to vascularization and cell migration. These events occur several times during organogenesis in both normal development and during tumor progression. Mechanisms of metalloprotease action underlying these events include the proteolytic cleavage of growth factors so that they can become available to cells not in direct physical contact, degradation of the ECM so that founder cells can move across tissues into nearby stroma, and regulated receptor cleavage to terminate migratory signaling. Most of these processes require a delicate balance between the functions of matrix metalloproteases (MMPs) or metalloprotease-disintegrins (ADAMs) and natural tissue inhibitors of metalloproteases (TIMPs). In this review, we discuss recent progress in identifying an essential role for metalloproteases in axon outgrowth, as an example of a focal invasive event. We also discuss the evolving concept of how MMPs might regulate stem cell fate during tumor development.

[1]  F M Watt,et al.  Out of Eden: stem cells and their niches. , 2000, Science.

[2]  M. Moses,et al.  A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma. , 2001, The American journal of pathology.

[3]  Z. Werb,et al.  Matrix Metalloproteinase-9/Gelatinase B Is Required for Process Outgrowth by Oligodendrocytes , 1999, The Journal of Neuroscience.

[4]  G. Bergers,et al.  Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects , 2000 .

[5]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[6]  M J Bissell,et al.  Tumors are unique organs defined by abnormal signaling and context. , 2001, Seminars in cancer biology.

[7]  Thiennu H. Vu,et al.  Matrix metalloproteinases: effectors of development and normal physiology. , 2000, Genes & development.

[8]  C. Heldin,et al.  PDGF-D is a specific, protease-activated ligand for the PDGF β-receptor , 2001, Nature Cell Biology.

[9]  Z. Werb ECM and Cell Surface Proteolysis: Regulating Cellular Ecology , 1997, Cell.

[10]  Y. Ma,et al.  Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Detmar,et al.  Thrombospondin‐2 plays a protective role in multistep carcinogenesis: a novel host anti‐tumor defense mechanism , 2001, The EMBO journal.

[12]  A. Krüger,et al.  Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. , 2001, Cancer research.

[13]  G. Christofori,et al.  Fibroblast growth factors are required for efficient tumor angiogenesis. , 2000, Cancer research.

[14]  Thiennu H. Vu,et al.  Don't mess with the matrix , 2001, Nature Genetics.

[15]  Z. Werb,et al.  How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.

[16]  A. Pozzi,et al.  Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  M. Tessier-Lavigne,et al.  Function of an axonal chemoattractant modulated by metalloprotease activity. , 2000, Science.

[18]  J. Sun,et al.  Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. , 2001, Cancer research.

[19]  J. Rothberg,et al.  PDGF-D, a new protease-activated growth factor , 2001, Nature Cell Biology.

[20]  L. Coussens,et al.  Inflammatory Cells and Cancer , 2001, The Journal of experimental medicine.

[21]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[22]  P. Sternberg,et al.  Working in the Post-Genomic C. elegans World , 2001, Cell.

[23]  A. Gaultier,et al.  Xenopus ADAM 13 is a metalloprotease required for cranial neural crest-cell migration , 2001, Current Biology.

[24]  Shigeyoshi Itohara,et al.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.

[25]  D. Bredesen,et al.  The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  I. Vlodavsky,et al.  Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. , 2001, The Journal of clinical investigation.

[27]  L. Matrisian,et al.  Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis , 1998, International journal of cancer.

[28]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[29]  Fiona M Watt,et al.  c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny , 2001, Current Biology.

[30]  P. Bornstein,et al.  Matricellular proteins as modulators of cell-matrix interactions: adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2. , 2000, Molecular biology of the cell.

[31]  M. Humphries,et al.  A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. , 1986, Science.

[32]  J G Flanagan,et al.  Regulated cleavage of a contact-mediated axon repellent. , 2000, Science.

[33]  W. Stetler-Stevenson,et al.  Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. , 2001, The American journal of pathology.

[34]  L. Devy,et al.  Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. , 2001, Cancer research.

[35]  T. Ferguson,et al.  Neuronal Matrix Metalloproteinase-2 Degrades and Inactivates a Neurite-Inhibiting Chondroitin Sulfate Proteoglycan , 1998, The Journal of Neuroscience.

[36]  Yihai Cao,et al.  Proteolytic processing regulates receptor specificity and activity of VEGF‐C , 1997, The EMBO journal.

[37]  N. Seeds,et al.  Plasminogen activator release at the neuronal growth cone. , 1981, Science.

[38]  P. Primakoff,et al.  The ADAM gene family: surface proteins with adhesion and protease activity. , 2000, Trends in genetics : TIG.

[39]  G. Giannelli,et al.  Role of Cell Surface Metalloprotease Mt1-Mmp in Epithelial Cell Migration over Laminin-5 , 2000, The Journal of cell biology.

[40]  E. Pasquale,et al.  Eph receptors and ephrin ligands: embryogenesis to tumorigenesis , 2000, Oncogene.

[41]  R. Jaenisch,et al.  Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of the host. , 1996, Oncogene.

[42]  G. Garcı́a-Cardeña,et al.  Oligomerization-Dependent Regulation of Motility and Morphogenesis by the Collagen Xviii Nc1/Endostatin Domain , 2001, The Journal of cell biology.

[43]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[44]  Eric S. Lander,et al.  Genomic analysis of metastasis reveals an essential role for RhoC , 2000, Nature.